Hepatitis B Vaccine: Four Decades on.
birth dose vaccination
hepatitis B virus
hepatitis D virus
hepatocellular carcinoma
liver transplant
vaccination guidelines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
01
03
2024
revised:
09
04
2024
accepted:
11
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Hepatitis B virus is a substantial contributor to cirrhosis and hepatocellular carcinoma (HCC) globally. Vaccination is the most effective method for prevention of hepatitis B and its associated morbidity and mortality, and the only method to prevent infection with hepatitis D virus. The hepatitis B vaccine has been used worldwide for more than four decades; it is available in a single- or triple-antigen form and in combination with vaccines against other infections. Introduction of the vaccine and administration at birth led to sustained decline in mother-to-child transmission, chronic hepatitis B, and HCC, however, global birth dose coverage remains suboptimal. In this review we will discuss different hepatitis B vaccine formulations and schedules, vaccination guidelines, durability of the response, and vaccine escape mutants, as well as the clinical and economic benefits of vaccination.
Identifiants
pubmed: 38675820
pii: vaccines12040439
doi: 10.3390/vaccines12040439
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.
Pays : United States